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Abstract
Purpose: The American College of Radiology (ACR) BI-RADS classification is the applicable for breast lesion assessment. 
BI-RADS categories 4 and 5 need to be followed by biopsy. The aim of our study was to evaluate the tissue biopsy-proven 
positive predictive value (PPV3) for BI-RADS 4 (and its subcategories) and for BI-RADS 5, and BI-RADS distribution, 
in comparison to ACR assumptions and literature.
Material and methods: We retrospectively analysed biopsies performed in our outpatient clinic in 2017. Our target 
group of patients consisted of 797 patients at the average age of 52 years.
Results: BI-RADS 5 constituted 12% of cases (95 cases), and BI-RADS 4 88% (698 cases). Within BI-RADS 4 subdivi-
sions there were 359 cases in 4a (45.3%), 215 in 4b (27%), and 124 in 4c (15.6%). Overall PPV3 was 34.8%. BI-RADS 5 
category PPV3 number was 97.89%. In category BI-RADS 4 the values of PPV3 equalled 26.22% without subdivision 
and 3.6%, 27.9%, and 88.7% for subcategories BI-RADS 4a, 4b, and 4c, respectively.
Conclusions: BI-RADS categorisation by radiologists in the studied group matches the literature data according to 
achieved PPV and BI-RADS percentage distribution. The stratification of cancer risk among categories was proven 
with Mann-Whitney U test p value < 0.005. There was a statistically important unaccepted difference of PPV3 be-
tween core biopsy and vacuum-assisted biopsy, which needs further investigation.
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Introduction
The American College of Radiology (ACR) BI-RADS 
classification comprises combined lexi con, result, and 
conclusion of breast examination. The classification was 
first introduced in 1993, seven years after its proposal, as 
a unified reporting for mammography examination. In 
2003 it was adapted to breast ultrasonography and magnet-
ic reso nance, and additionally, due to cancer risk of biopsy 
outcome, BI-RADS 4 was divided into three subcategories: 
4a, 4b, and 4c [1,2]. The recent fifth edition of the lexicon 
was published in 2013 [3]. BI-RADS category 5 is reserved 
for cancer-like lesions on diagnostic imaging. BI-RADS 4 
includes suspicious lesions with some likelihood of ma-
lignancy [3,4]. For both BI-RADS categories 4 and 5 le-
sions biopsy is mandatory, which makes them suitable for 
the calculation of biopsy-proven positive predictive value 
(PPV) [5,6].
In the United States of America, mammography BI-
RADS is under federal law and control (FDA’s MMG Quality 
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Standards Final Rule), but BI-RADS for ultrasonography is 
not subject to this regulation. Furthermore, the Food and 
Drug Administration (FDA) rule makes the BI-RADS 4 
subcategories non-obligatory.
In Europe, besides BI-RADS, there is the coexisting 
R1-5 score system proposed by the European Society of 
Breast Cancer Specialists (EUSOMA), but this has nev-
er gained popularity in Poland [7]. The Polish national 
breast cancer screening program is based on the BI-RADS 
lexicon but without the BI-RADS 4 subdivision. There is 
no legal implementation of BI-RADS classification for di-
agnostic purposes, but the scale is well known and com-
monly used among performers of breast diagnostics, and 
it is recommended [8]. According to the data from the 
National Mammography Database in the United States of 
America, about one third of BI-RADS 4 cases were report-
ed in subcategories [9]. From our experience this does not 
apply to Poland, because even if there is only BI-RADS 4 
in screening outcome, sustained on recall visit, it is to be 
subcategorised.
The classification seems to be free from the influence 
of patient factors like age or family history of breast cancer 
[10]. Therefore, the number of features linked to a per-
forming physician, influence BI-RADS categorisation per-
formance, among them the experience factor is the most 
important, and highlights the differences among groups 
of years of experience and the number of mammograms 
assessed yearly [11,12]. 
Histopathological assessment is the most reliable verifi-
cation of the BI-RADS categorisation. Besides confirmation 
or refutal of cancer, it provides data such as histopatholog-
ical type, cancer cell differentiation, and heterogeneity of 
tumour [13].
There is international agreement that surgical biopsy is 
a last-hope procedure and should not be commonly per-
formed [7,14]. Breast tissue biopsy procedures have proven 
their accuracy and have effectively replaced the surgical 
(open) biopsy for histopathology.
There are two types of tissue breast biopsies: core biop-
sy (CB) and vacuum-assisted biopsy (VAB). Both CB and 
VAB are characterised by a very high negative predictive 
value, reaching as much as 99.1% [15].
In Poland, applicable guidelines for CB have been 
approved by the cooperating societies of pathologists, 
oncologists, surgeons, and radiologists. VAB indications 
have been precisely defined as part of the Polish Minis-
try of Health Guidelines (third attachment of the list of 
guaranteed services of outpatient treatment procedures 
and their implementation conditions) [13,16]. Because 
Polish biopsy indication correlates with ACR diagnostic 
recommendations and BI-RADS classification is com-
monly used, we decided to evaluate BI-RADS categorisa-
tion from the perspective of our biopsy office, regardless 
of the basis of the diagnosis – weather it was based on 
mammography or ultrasonography performed together 
or separately.
Material and methods
The outcomes of all breast biopsies performed in 2017 in 
the Invasive Diagnostic Office of the diagnostic outpa-
tient clinic were the subject of our retrospective analy-
sis. The office offers its services to the Centre’s needs, i.e. 
screening, oncology, and oncological surgery outpatient 
clinics and within agreements with other health centres, 
including commercial biopsies. CB and VAB biopsies in 
the examined cases were performed under the control of 
an ultrasound examination.
In 2017 there were 895 biopsies performed. Exclusion 
criteria were the lack of pre-biopsy examination outcome, 
result without BI-RADS category, multiple biopsies of the 
same breast at the same time in multiple foci cancer oc-
currence, and axillary lymph nodes biopsies. The biopsies 
of breast lesions that proved to be lymph nodes on his-
topathological examination were included. Finally, there 
were 797 cases in the studied group. 
The group consisted of 795 women and two men with 
the average age of 52 years, ranging from 18 to 92 years.
There were 236 VAB and 561 CB performed. For the 
CB, 14G 2 cm wide window needle with an automated 
biopsy gun was used, whereas VAB was performed with 
an Encore system VS3000 with 7G, 10G, and 12G nee-
dles. Both CB and VAB biopsies were performed under 
the control of a Hitachi HI VISION Preirus ultrasound 
machine. All of the screening program patients (191) with 
ultrasound-proven lesions underwent CB procedure and 
constituted 24% of this group.
Statistical analysis
Mann-Whitney U test was used to assess differences be-
tween categories. χ2 test was performed to compare the 
CB and VAB groups. Because of the number of cases, the 
comparison of BI-RADS 5 and 4a was not available, and 
comparison of the 4c group was done with χ2 with Yates 
correction. All the statistical calculations were performed 
using Statistica software version 12.
Biopsy-proven predictive value (PPV3), which is the 
same as biopsy yield malignancy, also called positive biop-
sy rate, was calculated according to BI-RADS fifth edition. 
PPV3 = TP/(number of biopsies).
Results
A total of 797 biopsies were analysed. A complete list of 
the types of histopathology is presented in Table 1.
BI-RADS 5 constituted 12% of cases (95), and BI-RADS4 
88% (698 cases); with BI-RADS 4 subdivisions there were 
359 cases in 4a (45.3%), 215 in 4b (27%), and 124 in 4c 
(15.6%).
The number of diagnosed cancers was 276, which 
made up 34.8% of biopsies. In the BI-RADS 5 category, 93 
cancers were detected from a total of 95 biopsies, and the 
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PPV3 was 97.9%. In the BI-RADS 4 category, PPV3 was 
26.22% (183 cancers and 698 benign), in the division for 
4a, 4b, and 4c subcategories the PPV3 values were 3.6%, 
27.9%, and 88.7%, respectively (Table 2, Figure 1).
According to the type of biopsy, there were 248 can-
cers diagnosed by core biopsy (44.52% of CBs) and 28 by 
VAB (11.9% of VABs). In our study, the PPV3 differed 
between the CB and VAB groups (Table 3).
The most significant difference can be seen for the BI-
RADS 4b category, and was of statistical importance, as 
shown by the χ2 (p < 0.005). The positive predictive value 
for BI-RADS 4b lesions was 38.1% vs. 13.5% in CB com-
pared to VAB, respectively. According to χ2test with Yates 
correction, there is no statistically important difference 
between the CB and VAB groups in the BI-RADS 4c cate-
gory. The numbers of cases in category 4a and 5 were not 
suitable for statistical analysis. The PPV3 of the CB and 
VAB groups are presented in Figure 2. The Mann-Whit-
ney U test proves the difference in the number of cancers 
between 4a, 4b, 4c, and 5 with p value < 0.005. The same 
test p value < 0.005 was calculated for differences in the BI-
RADS 4 subcategories. U Mann-Whitney p value < 0.005 
was obtained for the same differences separately calculated 
in the CB and VAB groups.
Table 1. Histopathological outcomes
Histopathology No. of cases
Invasive ductal carcinoma 248
Fibroadenoma 190
Fibrocystic changes 168
Papilloma 33
Usual ductal hyperplasia 26
Invasive lobular carcinoma 17
Simple adenosis 15
Adenosis sclerosants 12
Columnar cell changes 12
Ductal carcinoma in situ 11
Hamartoma 7
Intramammary lymph node 6
Mastitis 6
Atypical ductal hyperplasia 5
Radial scar 5
Steatonecrosis 5
Atheroma 4
Duct ectasia 4
Lipoma 3
Atypical lobular hyperplasia 2
Flat epithelial atypia 2
Gynaecomastia 2
Haematoma 2
Abrikosow tumour 1
Apocrine metaplasia 1
Inflammatory granuloma 1
Lactating adenoma 1
Lymphoproliferative tissue 1
Metastatic lung cancer lymph node 1
Pseudoangiomatous stromal hyperplasia 1
Phyllodes tumour 1
Table 2. Positive predictive value (PPV) according to BI-RADS category
BI-RADS category Total No. Cancer No. PPV 3
4a 359 13 3.63%
4b 215 60 27.91%
4c 124 110 88.71%
5 95 93 97.89%
Summary 793 276 34.80%
Figure 1. Percentage of diagnosed cancers according to BI-RADS category
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Table 3. Positive predictive value according to BI-RADS category for core 
biopsy (CB) and vacuum-assisted biopsy (VAB)
BI-RADS CB group VAB group
4a 3.98% 3.01%
4b 38.10% 13.48%
4c 89.29% 83.33%
5 97.85% 100.00%
Figure 2. Percentage of diagnosed cancers
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Discussion
There were 31 types of histopathological outcomes (Ta- 
ble 1). Besides those expected, there were three, in our 
opinion, that required elaboration. The two of them are 
extra mammary metastatic disease. Metastases are uncom-
mon in breast and comprise no more than 2% of breast 
malignancy [17]. We diagnosed lymphoma and lung cancer 
as the most common in this group. of unknown origin [18]. 
Also of special concern is Abricossoff ’s tumour; a very 
rare benign neoplasm that can be found anywhere in the 
body, particularly the head and neck region, especially 
the tongue. Its location in the breast region is extremely 
rare – 6% of all granular cell carcinomas. On ultrasound, 
the mass appears solid, poorly defined, and with marked 
posterior shadowing [19]. BI-RADS categorisation in the 
studied group, especially in the case of BI-RADS 4c and 5, 
matches the literature data. BI-RADS 5 constitute 12.6% 
of cases, which is comparable with the 8% reported in 
“The Thai Journal of Surgery”, especially as this was based 
only on nonpalpable mammographic lesions, and those 
limitations did not apply to our work [20]. ACR BI-RADS 
4c was observed in 15.6% of cases and 4b in 27.1%, which 
is similar to the 12.6% and 31.8%, respectively, published 
by Elezaby et al. in “Radiology” in 2018 [9]. Compared 
with this assessment, there is clearly visible difference in 
the percentage of BI-RADS 4a. In our study, they con-
stituted 45.3%, because in the quoted paper there were 
more than 55%. There might be several reasons for such 
a difference. The National Mammography Database is 
not limited to the type of biopsy guidance, so it consists 
of data from stereotactic biopsies as well. The number of 
suspicious calcifications seen on mammography is to be 
the BI-RADS 4b category, and in most cases those lesions 
are not visible in ultrasound examination, which exclud-
ed some of BI-RADS 4b lesions from our assessment and 
might be the reason for this difference. It should be men-
tioned that this is only a suspicion and should be verified.
Breast cancer was diagnosed in 34.8% of biopsies and 
in 26.2% in ACR BI-RADS 4 category. This is almost per-
fect pitch, as the BI-RADS 4 category reported range is 
from 20% to 27% and PPV for BI-RADS 5 and 4 in ultra-
sound-guided biopsy resume was 35% [9,20-25]. The cate-
gory BI-RADS 4a is sometimes mentioned as a low cancer 
predictive factor, but because it is an indication for biop-
sy, we decided not to exclude it from our calculations for 
biopsy office, because it is still responsible for false posi-
tives and some true positives outcomes [26]. Mann-Whit-
ney U test (p < 0.005) revealed progressive increase of 
PPVs in the assessed categories and for BI-RADS 4a, b, 
and c subcategories alone (p < 0.005), which is another 
confirmation of BI-RADS classification compliance [9,27]. 
The positive predictive value (PPV3) in BI-RADS 5 cate-
gory was 97.89, which clearly matches the classification 
criteria and is adequate to previously reported, though 
there are some reports of lower PPV [20,28]. There were 
only two cases of false positive BI-RADS 5 in our study, so 
we decided to look into the histopathology of those cases. 
One proved to be atypical ductal hyperplasia and was 
further not upgraded after surgery.
The second false positive BI-RADS 5 lesion was an in-
flammatory atheroma.
Epidermoid cyst of the breast, when infected, can pres-
ent all of the suspicious characteristics suggesting carci-
noma, typical for BI-RADS 5 lesions, such as indistinct 
margins, echogenicity, and hyperechoic halo [29]. In the 
case of surrounding oedema, typical features like skin/sub-
cutaneous tissue location or a thin neck extending to the 
skin, suggesting its benign origin, can be entirely masked. 
All of these features can lead to the need for histological 
evaluation.
Positive predictive value for category 4, as mentioned, 
in general was 26.2%. PPV3 of BI-RADS 4a category was 
quite low (3.63%), compared to 7.6% from the National 
Mammography Database.
On the other hand, the increase of PPV3 was observed 
in the remaining BI-RADS 4 categories. 
For BI-RADS 4b PPV3 was calculated at 27.91% and 
was higher than that observed in the National Mammo-
graphy Database, where it was 22%, but the difference is 
lower than in the case of the BI-RADS 4c category. In our 
study PPV3 for BI-RADS 4c lesion is 88.71% vs. 69.3% in 
the previously mentioned case. The secret may lie in the 
relatively low number of cases in our study in comparison 
to NMB, but it also might be due to the miscategorisation, 
because it is not clear if the shift would have been from 
category 4 or from 4a to BI-RADS 3. 
There was, unaccepted for us, a difference in PPV3 
for BI-RADS 4b in the CB and VAB group (Table 3). 
The PPV3 in the CB group is almost three times higher 
than in VAB (38.10% vs. 13.48%). There might be a num-
ber of reasons for this difference. Trying to find the reasons 
underlying this difference, we have to admit that there are 
different indications for those types of biopsies. In our fa-
cility masses bigger than 5 mm are referred to CB; on the 
other hand, cystic lesions with mass, classical BI-RADS 4b, 
are always referred to VAB.
The other difference is due to National Screening Pro-
gram organisation. The program does not refund VAB; if 
there is need of one, the patient is referred to an oncolog-
ical or surgical oncology outpatient clinic for the proce-
dure. This results in high attendance of screening referrals 
in the CB group (191 from a total of 557). Because screen-
ing requirements (in Poland 5000 mammograms inter-
preted yearly) matches factor of interpretive performance, 
this might have an influence on the mentioned difference 
[11]. Due to the limitations of our hospital information 
system (HIS), we were unable to link the referring office 
with histopathological outcome, and, more important-
ly, after admission to the outpatient clinic the informa-
tion about prior screening program attendance was lost. 
Although this is interesting, finding it should be under 
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further investigation, but in our case it must be done from 
screening examination office data, not from biopsy office 
data.
Conclusions
The work has proven the stratification of cancer risk in BI-
RADS biopsy-indicating criteria. It shows that among the 
biopt lesions the categories match those indicated in the 
fifth edition of the ACR BI-RADS lexicon. An unaccept-
ed difference in PPV3 between CB and VAB in category 
BI-RADS 4b was stated, which needs to be the subject of 
further investigation.
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